Aurora Rejects Curaleaf's Revised $5 Bid, Reveals Active Strategic Alternatives Process
ACB sits 63% above its 52-week low of $2.56.
Summary
Aurora's board unanimously recommends shareholders reject Curaleaf's revised hostile bid of US$5.00 per share, up from US$4.00, citing an updated fairness opinion that the offer remains inadequate. The company argues the bid would use Aurora's own cash to fund the acquisition and exposes shareholders to Curaleaf's inflated stock. More importantly, Aurora discloses its Special Committee is actively exploring strategic alternatives, has entered confidentiality and standstill agreements with multiple parties, and is in discussions that could lead to a superior transaction or a standalone path. The bid remains open until December 4, 2026, giving the board time to pursue alternatives. This follows the initial rejection in September and the revised bid on October 6; the new disclosure of multiple parties under NDA is a material escalation in the defense.
Updates
· SEC 6-K — Aurora filed a 6-K with the full press release and Notice of Change details; bid open until December 4, 2026.
At the time of this announcement, ACB was trading at $4.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $271.4M. The 52-week trading range was $2.56 to $6.36. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.